Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps-Reference-Cited by-同舟云学术

Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps

Published:2019-03-01 Issue:6 Volume:59 Page:779-783
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Eke Ahizechukwu C.¹²^ORCID,Mirochnick Mark H.³

Affiliation:

1. Division of Maternal Fetal Medicine & Clinical Pharmacology; Department of Gynecology & Obstetrics; Johns Hopkins University School of Medicine; Baltimore MD, USA

2. Doctoral Training Program (PhD); Graduate Training Program in Clinical Investigation (GTPCI); Johns Hopkins University School of Public Health; Baltimore MD, USA

3. Division of Neonatology; Department of Pediatrics; Boston University School of Medicine; Boston MA, USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.1397/fullpdf

Reference26 articles.

1. FDA revises certain antiretroviral drug labeling to not recommend cobicistat during pregnancy. FDA News, Issue 33, November 2018. https://www.ascpt.org/Resources/ASCPT-News/View/ArticleId/22744/FDA-News-Issue-33-November-2018

2. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences;Tseng;Ann Pharmacother,2017

3. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results;Gallant;J Infect Dis,2013

4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial;DeJesus;Lancet,2012

5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons;Frontiers in Medicine;2023-11-29

2. Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response;The Journal of Clinical Pharmacology;2023-06

3. Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV);Expert Review of Anti-infective Therapy;2022-09-20

4. Prediction and prevention of preterm birth in pregnant women living with HIV on antiretroviral therapy;Expert Review of Anti-infective Therapy;2022-03-01

5. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics;Journal of Basic and Clinical Physiology and Pharmacology;2021-12-08